Abstract:Yuanyuan Zhu, Wei Zhang, Jing Chen Department of Pharmacy, Qingdao Hospital of Traditional Chinese Medicine, Qingdao Hiser Hospital Affiliated with Qingdao University, Qingdao, Shandong Province, People's Republic of China Correspondence: Jing Chen, Department of Pharmacy, Qingdao Hospital of Traditional Chinese Medicine, Qingdao Hiser Hospital Affiliated with Qingdao University, 4 Renmin Road, Qingdao, Shandong Province, 266000, People's Republic of China, Email Objective: This study aimed to develop a binary nanodrug-delivery system decorated with aptamers (APs) and transferrin (Tf) and loaded with daunorubicin (Drn) and luteolin (Lut) for the treatment of leukemia. Methods: Oligonucleotide AP- and Tf-contaiing ligands were designed and synthesized separately. AP-decorated Drn-loaded nanoparticles (AP-Drn NPs) and Tf-Lut NPs were prepared by self-assembly. An AP- and Tf-codecorated Drn- and Lut-coloaded nanodrug-delivery system (AP/Tf-Drn/Lut NPs) was prepared by self-assembly of AP-Drn NPs and Tf-Lut NPs. In vitro and in vivo efficiency of the system was evaluated on leukemia cell line and cell-bearing mouse model in comparison with single ligand–decorated, single drug–loaded and free-drug formulations. Results: AP/Tf-Drn/Lut NPs were spherical and nanosized (187.3± 5.3 nm) and loaded with about 85% of drugs. In vitro cytotoxicity of AP/Tf-Drn/Lut NPs was remarkably higher than single ligand–decorated ones. Double drug–loaded AP/Tf-Drn/Lut NPs exhibited higher tumor-cell inhibition than single drug–loaded ones, which showed a synergic effect of the two drugs. AP/Tf-Drn/Lut NPs achieved the most efficient antileukemic activity and absence of toxicity in vivo. Conclusion: The present study showed that AP/Tf-Drn/Lut NPs are a promising drug-delivery system for targeted treatment of leukemia, due to the synergic effect of the two drugs in this system. The limitations of this system include stability during large-scale production and application from bench to bedside. Keywords: acute myeloid leukemia, daunorubicin, luteolin, aptamer, transferrin, nanodrug-delivery system Acute myeloid leukemia (AML), a heterogeneous hematologic malignancy, is the most common acute leukemia among adults. 1 Clinical outcomes of patients with AML are still poor, with 65 years). 2,3 Current treatmentsfor AML mainly consist of standard chemotherapy (a combination of cytarabine and daunorubicin [Drn] or idarubicin), targeted therapy using FLT3 inhibitors, including midostaurin, quizartinib, and cabozantinib, and immunotherapy, eg, gemtuzumab ozogamicin (anti-CD33 monoclonal antibody conjugated with calicheamicin). 3–6 Unfortunately, current treatments still have therapeutic obstacles, including lower compliance, because of serious toxicity and therapeutic efficacy due to drug resistance. Therefore, it is urgent to exploit new therapeutic strategies to improve treatment outcomes. Nanoparticle (NP)-based combination therapy has attracted extensive attention in recent years for AML therapy. Currently, there are two liposomal formulations available in the clinic for the treatment of HM (liposomal Drn [DaunoXome] and liposomal cytarabine + Drn [CPX-351/VYXEOS]). 7,8 Phase III results have proven that compared to free drug (Drn and cytarabine), the liposomal formulation codelivering Drn and cytarabine significantly improves median overall survival (9.56 vs 5.95 months) and overall remission rate (47.7% vs 33.3%) for elderly patients with newly diagnosed high-risk secondary AML. 9 This brings forth a new era for AML patients based on Drn-combination nanoformulation therapy. An anthracycline topoisomerase inhibitor, Drn is a broad-spectrum antihematologic malignancy agent for AML, acute nonlymphocytic leukemia of adults, and acute lymphocytic leukemia of children and adults. 10 However, multidrug resistance hampered the further clinical application of Drn injections. Recently, Chinese herbal medicine and NPs have attracted research interest to overcome multidrug resistance. 11,12 Luteolin (Lut; 3′,4′,5,7-tetrahydroxyflavone) has been applied in traditional Chinese medicine for treating various diseases, including inflammatory disorders, angiocardiopathy, and cancer. 13,14 Various studies have demonstrated that Lut has the ability to enhance the antileukemia capacity of chemotherapeutic agents and anti–multidrug resistance by upregulation of P-gp and BCL2, downregulation of MCL1 expression, and inducing apoptosis of HL60 cells that was associated with c-Jun activation and histone H3 acetylation–mediated Fas/FasL expression. 15–18 We were unable to find literature -Abstract Truncated-

Adriamycin/Nucleophosmin Binding Protein-Conjugated Nanoparticle (Adr-Pms-npmbp) Enhances Anti-Leukemia Activities of Adriamycin in Acute Lymphoblastic Leukemia Cells

Doxorubicin/Nucleophosmin Binding Protein-Conjugated Nanoparticle Enhances Anti-leukemia Activity in Acute Lymphoblastic Leukemia Cells in Vitro and in Vivo

PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation

PNC¯27 Targeting Plasma Membrane HDM2: A Potentially Novel Therapeutic Approach for Acute Myeloid Leukemia (AML)

Liver Targeting and the Delayed Drug Release of the Nanoparticles of Adriamycin Polybutylcyanoacrylate in Mice

Preclinical Evaluation of Adjuvant Therapy with Amd3100 for Drug Resistant Philadelphia Chromosome Positive and Negative All

Reversal in Multidrug Resistance by Magnetic Nanoparticle of Fe3o4 Loaded with Adriamycin and Tetrandrine in K562/A02 Leukemic Cells

Ultrasound Mediated Drug-Loaded Nanoparticles Crossing Cell Membranes As A New Strategy To Reverse Multidrug Resistance In Human Leukemia Cell Line K562/A02

Lanthanide-doped nanoparticles conjugated with an anti-CD33 antibody and a p53-activating peptide for acute myeloid leukemia therapy

Decreased expression of nucleophosmin/B23 increases drug sensitivity of adriamycin-resistant Molt-4 leukemia cells through mdr-1 regulation and Akt/mTOR signaling

Magnetic Nanoparticles Fe3O4 Synergy with Adriamycin and Arsenic Trioxide Reverse Multidrug Resistance in Lymphoma in Vitro

Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia.

Polybutylcyanoacrylate Magnetic Nanoparticles As Carriers of Adriamycin.

PLGA-PLL-PEG-Tf-based Targeted Nanoparticles Drug Delivery System Enhance Antitumor Efficacy Via Intrinsic Apoptosis Pathway

Binary Nanodrug-Delivery System Designed for Leukemia Therapy: Aptamer- and Transferrin-Codecorated Daunorubicin- and Luteolin-Coloaded Nanoparticles

Targeting Epigenetic Pathway with Gold Nanoparticles for Acute Myeloid Leukemia Therapy

CXCR4 and CD44 Dual-Targeted Prussian Blue Nanosystem with Daunorubicin Loaded for Acute Myeloid Leukemia Therapy

Abstract 4710: The polymeric AMD3100 based drug PAMD-Ch17 induces its anti-leukemic effects in a CXCR4 independent mechanism

Development of CD33-Targeted Dual Drug-Loaded Nanoparticles for the Treatment of Pediatric Acute Myeloid Leukemia

Nanoparticle Targeted Therapy Against Childhood Acute Lymphoblastic Leukemia

Codelivery of BCL2 and MCL1 Inhibitors Enabled by Phenylboronic Acid-Functionalized Polypeptide Nanovehicles for Synergetic and Potent Therapy of Acute Myeloid Leukemia.